Literature DB >> 6101290

Treatment of the patient after myocardial infarction. The last decade and the next.

E Braunwald.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101290     DOI: 10.1056/NEJM198001313020510

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Disaggregation and reaggregation of 'irreversibly' aggregated platelets: a method for more complete evaluation of anti-platelet drugs.

Authors:  G H Rao; J G White
Journal:  Agents Actions       Date:  1985-07

Review 2.  Recent advances in cardiology.

Authors:  E A Rodrigues; D J Coltart
Journal:  Postgrad Med J       Date:  1982-08       Impact factor: 2.401

3.  Prostacyclin as an endogenous anti-arrhythmic agent.

Authors:  U N Das
Journal:  Basic Res Cardiol       Date:  1983 Nov-Dec       Impact factor: 17.165

4.  Secondary prevention of myocardial infarction--the present state of the ART.

Authors:  J R Mitchell
Journal:  Br Med J       Date:  1980-05-03

5.  Sulphinpyrazone metabolism during long-term therapy.

Authors:  A K Pedersen; P Jakobsen
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

6.  Sulphinpyrazone and renal function following myocardial infarction.

Authors:  S L Choudhury; S H Taylor; G Wieringa; R Swaminathan; D B Morgan
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.

Authors:  C Dahinden; J Fehr
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.